Ivestatin Therapeutics Revenue

Pharmaceutical Manufacturing • Barcelona, Catalonia, Spain • 1-10 Employees

Ivestatin Therapeutics revenue & valuation

Annual revenue	$171,110
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$547,552
Total funding	No funding

Key Contact at Ivestatin Therapeutics

Eugeni Montull

Director asuntos médicos

Company overview

Headquarters	Barcelona, Catalonia, Spain
NAICS	3254
Employees	1-10

About Ivestatin Therapeutics

IVESTATIN THERAPEUTICS is a new spin-off from the Research Institute of the Hospital de la Santa Creu i Sant Pau and Gendiag, a Barcelona-based Biotechnology Company. At Ivestatin Therapeutics we aim to become the world leader in innovative therapeutic solutions in the reduction of ischemic damage. SHIELD4Heart, our lead compound, is an innovative and safe first-line therapy to prevent and reduce ischemic damage following an Acute Coronary Syndrome (ACS) event, currently the world's leading cause of death. SHIELD4Heart reduces the infarct area by limiting ischaemic damage through a multiTarget Cell Protection mechanism (mTCP) which is activated by atorvastatin. SHIELD4Heart is administered intravenously before reperfusion, the only method to obtain a rapid onset of action in ACS. It can be introduced seamlessly into the ACS clinical pathway with no disruption to current management protocols. To date, we have obtained promising in vivo data in several animal models (mouse, rat and pig) and, we are ready to start a fast pathway to first-in-human clinical trials beginning within 18 months.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Funding Data

Ivestatin Therapeutics has never raised funding before.

Frequently asked questions

Ivestatin Therapeutics is located in Barcelona, Catalonia, ES.

Ivestatin Therapeutics generates an estimated annual revenue of $171,110. This revenue figure reflects the company's market position and business performance in its industry.

Ivestatin Therapeutics has an estimated valuation of $547,552. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Ivestatin Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Ivestatin Therapeutics

Eugeni Montull

Director asuntos médicos

4.8

40,000 users